CERS Stock Price Cerus Corp Stock Quote U.S.: Nasdaq

This suggests a possible upside of 188.5% from the stock’s current price. View analysts price targets for CERS or view top-rated stocks among Wall Street analysts. Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma.

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Cerus in the last year.

Our Services

This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher… Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. A positive regulatory development sent Cerus’ shares higher today.

3 brokers have issued 12-month price targets for Cerus’ shares. Their CERS share price forecasts range from $3.75 to $6.00. On average, they expect the company’s share price to reach $4.88 in the next twelve months.

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman has an approval rating of 35% among the company’s employees. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Cerus (CERS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Private Companies

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

• Investors headed for the exits after the company announced an unexpected product supply shortage.
• The monthly returns are then compounded to arrive at the annual return.
• Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.
• For example, a price above its moving average is generally considered an upward trend or a buy.
• This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher…

The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $160.00 million-$165.00 million, compared to the consensus revenue estimate of $172.56 million. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

30 days

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 what is meaning of demat account out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. One share of CERS stock can currently be purchased for approximately $1.69. The biotech was one of 10 stocks that are to be deleted from the S&P SmallCap 600 to make room for S&P MidCap 400 titles moving into the former index. Among these incoming S&P SmallCap 600 constituents are pizza slinger Papa John’s International, storied athletic apparel retailer Foot Locker, and JetBlue Airways. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should “hold” CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares.

Since then, CERS shares have decreased by 53.7% and is now trading at $1.69. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

Cerus now sees 2017 product revenue of $38 mln to $46 mln vs prior $43 mln to $48 mln

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.

The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA. Unfortunately for shareholders of Coherus BioSciences (CHRS 1.28%), that’s what happened https://1investing.in/ to their company after market hours last Friday. Following that, its stock price was falling by 10% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence.

The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Cerus’ stock was trading at $3.65 at the beginning of 2023.

Investors headed for the exits after the company announced an unexpected product supply shortage. The company provided an update on the most pressing issue facing the biopharma stock in 2017. A better-than-expected outlook after the company’s first-quarter report is lifting more than spirits.

After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Cerus updated its FY 2023 earnings guidance on Wednesday, August, 2nd.

The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.

Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

Eric Volkman has no position in any of the stocks mentioned. While the “index effect” often occurs with stock inclusion or deletion from a popular index, it tends to be short-lived. After all, being listed barely impacts a company’s fundamentals, if at all. But getting the boot means that a stock can fall off the radar of the many index funds that comb such collections for investment opportunities. The changes, which also affect the bellwether large-cap S&P 500 index, will take effect before market open on Monday, Sept. 18.

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Late that day, S&P Dow Jones Indices — operator of the high-profile indexes that bear the S&P name — effected its typical quarterly rebalance of several indexes. These changes will involve the S&P SmallCap 600 index, the group of stocks that formerly included Coherus.

The popular growth investor publishes her daily transactions. Cathie Wood keeps buying Tesla as well as some of her smaller holdings. Positive pivotal trial results bode well for the company’s new blood transfusion product. Preliminary third-quarter results pleased the crowd at the company’s annual investor meeting. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.

Live by the index, die by the index — being included in a well-known collection of stocks can really help a company’s visibility and boost investor morale. The opposite effect can kick in if it gets kicked out of an index. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Cerus’ stock is owned by many different retail and institutional investors.

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat’s FREE daily newsletter.